Chronic Insomnia Linked to Increased Risk of Cardiovascular Disease, Diabetes, Depression: Study


Chronic Insomnia Linked to Increased Risk of Cardiovascular Disease, Diabetes, Depression: Study

A good night’s rest does more than just give you beauty sleep. New research suggests your sleep patterns could be linked to serious underlying health issues.

Adults suffering from chronic insomnia for at least a decade face significantly higher risks of developing conditions like heart disease, diabetes, and depression, according to the results.

However, the news isn’t all bad—the study also found that adults who make up for lost sleep on the weekends by taking naps are not at an increased risk for these underlying health problems.

More Than Half of Americans Exhibit Problematic Sleep Habits

The study, published in Psychosomatic Medicine, analyzed data from the Midlife in the United States (MIDUS), a national sample of continental U.S. residents between 25 and 74 years of age. The dataset included information on the sleep habits and chronic health conditions of approximately 3,700 individuals collected from 2004 to 2006 and from 2013 to 2017.

Four distinct sleep patterns were identified:

  • Good sleepers: People with “optimal sleep health across all dimensions”
  • Insomnia sleepers: People suffering from clinical insomnia, including short sleep duration, high daytime exhaustion, and difficulty falling asleep
  • Weekend catch-up sleepers: Those who may have irregular or shorter sleep during the week but longer sleep times on weekends or non-work days
  • Nappers: Those who typically slept well but took frequent daytime naps

More than half of the participants were either insomnia sleepers or nappers, both of which are considered sub-optimal sleep patterns.

The data revealed that people with chronic insomnia were 72-188 percent more likely to develop cardiovascular disease, diabetes, depression, and frailty compared to good sleepers. Overall, being an insomnia sleeper increased a person’s risk of a chronic condition by 28-81 percent.

The study found that “being a napper at any timepoint” was related to increased risks for diabetes, cancer and frailty

The researchers also noted that those with lower education and those who were unemployed were more likely to be insomnia sleepers, while older adults and retirees were more likely to be nappers.

Sleep Patterns Proven Difficult to Change

The study also found that sleep patterns tend to be remarkably resistant to change.

Overall, 77 percent of participants remained in the same sleep pattern, or “phenotype,” over the study period. More specifically, 90 percent of insomnia sleepers and 97 percent of nappers maintained those same habits throughout the study.  Those categorized as weekend catch-up sleepers were more likely to transition into being nappers.

“These results may suggest that it is very difficult to change our sleep habits because sleep health is embedded into our overall lifestyle,” Soomi Lee, associate professor of human development and family studies at Penn State and the lead researcher, said in a press release. “It may also suggest that people still don’t know about the importance of their sleep and about sleep health behaviors.”

Despite the apparent rigidity of sleep patterns, education and consistent practice can help facilitate positive changes over time, according to Mr. Lee.

He recommends that public health efforts focus on educating people about proper sleep hygiene. The U.S. Centers for Disease Control and Prevention recommends five key tips:

  • Maintain consistency by going to bed at the same time each night.
  • Create a sleep-conducive environment—dark, cool, and quiet.
  • Remove electronic devices from the bedroom.
  • Avoid large meals, caffeine, and alcohol close to bedtime.
  • Get enough physical activity during the day to support better sleep at night.

What are the guideline recommendations for pharmacological treatment of chronic insomnia disorder in adults?


Recommendations for pharmacotherapy for chronic insomnia disorder in adults:

  • To decide whether to add pharmacological therapy in adults with chronic insomnia disorder who remain non-responsive to cognitive behavioural therapy for insomnia (CBT-I) alone, a shared decision-making approach should be used to discuss the benefits, harms, and costs of short-term medication use. Improved sleep outcomes, including sleep onset latency and total sleep time, improved global outcomes in the general population and older adults are the advantages of pharmacotherapy.[1]
  • The U.S. Food and Drug Administration (FDA) approved several drugs for insomnia for short-term use (4-5 weeks), and patients should not continue using the drugs for extended periods. The patient should resume using the tools acquired during CBT-I following drug treatment. If the remission does not occur within 7-10 days of treatment, patients should be re-evaluated. Before continuing with drugs, secondary causes of insomnia (e.g., depression, substance misuse, dyspnoea, or restless legs syndrome) should be evaluated.
  • Adults should be treated with Suvorexant and Doxepin for sleep maintenance insomnia.
  • Eszopiclone, Zolpidem, and Temazepam (15 mg) should be used to treat sleep onset and sleep maintenance insomnia.
  • Sleep onset insomnia should be treated with Zaleplon, Triazolam (0.25 mg), and Ramelteon.[2]

Drugs used for the treatment of chronic insomnia:

Drug nameDosage (mg)
Nonbenzodiazepine sedative ‘Z-drug’ hypnotics 
Eszopiclone1-3
Zaleplon5-10
Zolpidem5-10
Zolpidem, continuous release6.25-12.5
Zolpidem, sublingual1.75/3.5
Zolpidem, oral spray5-10
Melatonin agonists 
Melatonin1
Ramelteon8
Antidepressants 
Amitriptyline (Off-label)25-150
Doxepin3-6
Mirtazapine (Off-label)7.5-15
Nortriptyline25-150
Trazodone (Off-label)50-100
Orexin receptor antagonist 
Suvorexant (not recommended in patients with severe hepatic impairment).5-20
Lemborexant (not recommended in patients with severe hepatic impairment).5, 10
Daridorexant10, 25, 50
Antihistamines 
Diphenhydramine (Off-label)25-50
Doxylamine (Off-label)25-50
Hydroxyzine50-100
Antipsychotics 
Olanzapine2.5-20
Quetiapine50-400
Risperidone0.25-6
Anticonvulsants 
Gabapentin300-600
Pregabalin50-3003

Treating Chronic Insomnia Overnight.


Intensive sleep retraining is a novel, brief, and effective treatment for sleep-onset insomnia.

Stimulus control therapy (SCT) is the major behavioral treatment for chronic insomnia. These authors studied a novel, 25-hour, nonpharmacological treatment, intensive sleep retraining (ISR), alone and in combination with SCT.

The 79 adults (mean age, 41) had sleep-onset insomnia and no other sleep disorder or major psychiatric illness. They were randomized to sleep hygiene advice (control condition), SCT (5 weekly appointments with a psychologist, focusing on reassociating bed/bedroom with sleep and establishing a consistent sleep schedule), ISR followed by SCT plus sleep hygiene, or ISR followed by sleep hygiene. ISR was conducted in a sleep laboratory and started at 10:30 PM after a restricted, 5-hour sleep the previous night. Over the next 25 hours, participants underwent 50 half-hour sleep trials. At each trial, participants who fell asleep within 20 minutes were awakened after 3 minutes of polysomnographically confirmed sleep, asked whether they thought they had been asleep, and told that they had been asleep.

All three active treatments significantly improved sleep-onset latency and total sleep time, compared with sleep hygiene. ISR produced the most rapid improvement, over the first week. Six weeks after treatment, response (sleep-onset latency, <30 minutes or <50% of baseline) was seen in 61% of the SCT+ISR group, 47% of the ISR group, and 38% of the SCT group. Gains in all groups were largely maintained through 6 months of follow-up.

Comment: As both authors and commentators explain, intensive sleep retraining counters the conditioned psychophysiological arousal that maintained insomnia, allows massed practice in falling asleep rapidly, and provides feedback about objectively recorded sleep onset. The rapid and sustained effects of ISR make it an exciting new treatment. Clinicians should consider this option for their patients with chronic sleep-onset insomnia. Eventual development of home-based, less expensive versions of ISR should make it more widely available.

Source: Journal Watch Psychiatry